April 9, 2021 07:22 AM EDT
Coronavirus

Covid-19 roundup: Lil­ly/In­cyte's Olu­mi­ant plus remde­sivir com­bo whiffs PhI­II; France rec­om­mends mix­ing vac­cines among younger As­traZeneca re­cip­i­ents

Max Gelman

Senior Editor

Eli Lil­ly has won three emer­gency use au­tho­riza­tions for Covid-19 treat­ments, two for its an­ti­body cock­tail con­tain­ing bam­lanivimab and one fea­tur­ing its In­cyte-parn­tered drug Olu­mi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times